CS
SNDX icon

Candriam SCA’s Syndax Pharmaceuticals SNDX Stock Holding History

Candriam SCA’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37M Buy
1,696,040
+770,708
+83% +$16M 0.17% 126
2026
Q1 		$21.6M Hold
925,332
– – 0.11% 182
2025
Q4 		$19.4M Hold
925,332
– – 0.1% 191
2025
Q3 		$14.2M Buy
925,332
+250,247
+37% +$3.28M 0.07% 221
2025
Q2 		$6.32M Buy
675,085
+224,650
+50% +$2.47M 0.04% 315
2025
Q1 		$5.53M Sell
450,435
-96,730
-18% -$1.36M 0.03% 312
2024
Q4 		$7.23M Sell
547,165
-451,454
-45% -$7.73M 0.04% 304
2024
Q3 		$19.2M Buy
998,619
+28,513
+3% +$589K 0.11% 184
2024
Q2 		$19.9M Sell
970,106
-74,926
-7% -$1.57M 0.12% 169
2024
Q1 		$24.9M Buy
1,045,032
+24,000
+2% +$535K 0.16% 139
2023
Q4 		$22.1M Buy
1,021,032
+781,022
+325% +$12M 0.15% 151
2023
Q3 		$3.48M Hold
240,010
– – 0.02% 357
2023
Q2 		$5.02M Sell
240,010
-14,864
-6% -$309K 0.04% 331
2023
Q1 		$4.95M Buy
+254,874
New +$6.34M 0.03% 366
2021
Q2 		– Sell
-25,671
Closed -$548K – 936
2021
Q1 		$548K Hold
25,671
– – ﹤0.01% 704
2020
Q4 		$571K Sell
25,671
-332,701
-93% -$6.9M ﹤0.01% 717
2020
Q3 		$5.29M Buy
358,372
+10,914
+3% +$166K 0.05% 347
2020
Q2 		$5.15M Buy
+347,458
New +$5.29M 0.05% 325
2018
Q1 		– Sell
-70,000
Closed -$613K – 786
2017
Q4 		$613K Buy
+70,000
New +$693K 0.01% 647

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Candriam SCA's SNDX Position: Q2 2026 in Review

Candriam SCA increased its Syndax Pharmaceuticals (SNDX) stake by 83% in Q2 2026, buying an estimated $16M and bringing the position to 1,696,040 shares worth $37M. The position accounts for 0.17% of the portfolio, ranked #126.

Candriam SCA first reported a position in SNDX in Q4 2017 and has held it in 19 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Candriam SCA held 1,696,040 shares of Syndax Pharmaceuticals worth $37M as of Q2 2026.
  • Candriam SCA bought 770,708 Syndax Pharmaceuticals shares in Q2 2026, an estimated $16M.
  • Syndax Pharmaceuticals made up 0.17% of Candriam SCA's portfolio in Q2 2026, its #126 holding.
  • Candriam SCA first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.